Organoidsciences Ltd
Company Profile
Business description
Organoidsciences Ltd is a biotechnology company specializing in organoid technology, developing regenerative therapeutics and drug discovery solutions based on three-dimensional organoids. Its business includes ATORM, an organoid-based regenerative therapeutics pipeline, and ODISEI, an organoid-based drug discovery platform. ATORM is a regenerative therapeutic pipeline leveraging organoids derived from various human tissues, including the intestine and salivary gland, to develop novel treatments for a wide range of diseases. ODISEI is an organoid-based drug discovery solution that utilizes disease-specific organoids-including tumor, viral infection, intestinal, and skin organoids-to predict and evaluate human biological responses.
Contact
338 Pangyo-ro
6th floor, Bundang-gu
Gyeonggi-do
Seongnam-si
KORT: +82 27072024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
86
Stocks News & Analysis
stocks
Steep downgrade for wide moat share
stocks
The strange effect of the 30% minimum capital gains tax
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,979.30 | 38.70 | 0.43% |
| CAC 40 | 8,252.66 | 183.58 | -2.18% |
| DAX 40 | 24,897.45 | 567.80 | -2.23% |
| Dow JONES (US) | 52,335.48 | 589.67 | -1.11% |
| FTSE 100 | 10,489.04 | 176.84 | -1.66% |
| HKSE | 24,199.46 | 702.57 | 2.99% |
| NASDAQ | 25,823.82 | 5.13 | 0.02% |
| Nikkei 225 | 66,819.05 | 1,437.91 | -2.11% |
| NZX 50 Index | 13,665.18 | 97.61 | -0.71% |
| S&P 500 | 7,478.90 | 24.95 | -0.33% |
| S&P/ASX 200 | 8,785.10 | 47.50 | 0.54% |
| SSE Composite Index | 3,970.88 | 19.36 | -0.49% |